axSpA market seen rising to $9.83 billion by 2030

The global axial spondyloarthritis market is projected to grow from $6.56 billion in 2025 to $7.09 billion in 2026, with The Business Research Company forecasting $9.83 billion by 2030. Growth is tied to wider treatment use, better diagnosis and an aging population, while North America leads and Asia-Pacific is expected to grow fastest.

Why it matters: - Axial spondyloarthritis is a chronic inflammatory disease that can cause persistent back pain, stiffness and reduced mobility. - Market growth reflects stronger diagnosis and treatment adoption, which can affect patient access to therapies and long-term care planning. - An aging population is expanding the pool of people who may need screening, treatment and ongoing management.

What happened: - The Business Research Company published its Axial Spondyloarthritis (axSpA) Market Global Market Report 2026 on Nov. 4, 2026. - The report estimates the market will grow from $6.56 billion in 2025 to $7.09 billion in 2026. - The report forecasts the market will reach $9.83 billion by 2030. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offered a free sample of the report and a full report.

The details: - The market is projected to post an 8.1% CAGR from 2025 to 2026. - The report projects an 8.5% CAGR through 2030. - Near-term growth is linked to greater awareness of inflammatory spinal disorders, broader use of TNF inhibitors, better diagnostic imaging, growth in rheumatology specialty care and patient adherence efforts. - Longer-term growth is tied to rising use of JAK inhibitors and interleukin therapies, personalized medicine investment, early screening programs, digital disease monitoring and biologic drug development. - The report highlights rising uptake of biologic therapies, expanded targeted anti-inflammatory drugs, earlier diagnosis and monitoring, personalized regimens and deeper use of digital health tools. - Axial spondyloarthritis affects the axial skeleton, including the spine and sacroiliac joints. - Inflammation in the sacroiliac joints can lead to ongoing pain and stiffness. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

Between the lines: - The report’s demand story is not just about new medicines. It is also about earlier detection, specialty care access and digital monitoring. - Ageing demographics are a structural tailwind for diagnosis and treatment uptake, especially as older adults face higher healthcare needs. - The regional split suggests mature markets are leading today, while faster healthcare investment in Asia-Pacific is expected to drive the next phase of expansion. - England had 11 million residents aged over 65 in 2023, and Age UK projects that figure will rise by 10% in five years and 32% by 2043. - Age UK also projects the 85-and-older population in England will rise by 8.2% in five years and 62.7% by 2043.

What's next: - The report expects broader use of biologics, JAK inhibitors and IL therapies to shape market growth through 2030. - More screening and digital monitoring tools are likely to become more common as treatment pathways evolve. - The Business Research Company said its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics and updated trend analysis. - The company lists Saumya Sahay as a contact for more information at marketing@tbrc.info and the phone numbers provided in the release.

The bottom line: - axSpA is moving from a niche inflammatory-disease market to a larger therapy and diagnostics opportunity, with aging populations and better detection helping drive the next wave of growth.